REACH Registry Demonstrates That Multiple Arterial Disease,Locations Sharply Increase the Risk of Major CV Events in,Outpatients With Atherothrombosis (

HOME >> MEDICINE >> TECHNOLOGY

REACH Registry Demonstrates That Multiple Arterial Disease,Locations Sharply Increase the Risk of Major CV Events in,Outpatients With Atherothrombosis

- The Reduction of Atherothrombosis for Continued Health (REACH)

- Registry 1-Year Results

PARIS, March 20, 2007 /PRNewswire/ --The REACH Registry 1-year results paper published today in the Journal of the American Medical Association (JAMA) show that outpatients with atherothrombosis have a surprisingly high risk of death or major cardiovascular illness, especially if more than one vascular bed is diseased. REACH also documented high event rates that accrued almost linearly over time - in contrast to the sharp rise followed by a leveling off of event rates that is usually seen in patients discharged from hospital after acute events. REACH is the first international outpatient registry to characterize the real-world burden of atherothrombotic disease worldwide (REACH).

- Within a year, around one in seven patients will die, experience a heart attack or stroke, or be hospitalized from a complication arising from atherothrombosis - clogged arteries in the heart, brain or legs.

- Patients with atherothrombosis in the legs (peripheral arterial disease: PAD) have a one in five (21%) chance of dying, having a heart attack or stroke or being hospitalized due to cardiovascular reasons within one year.

- Over the same period of time, for patients who have atherothrombosis in more than one area (heart, brain and/or legs) this risk doubles.

- The risk increases dependent on the number of arterial beds affected; with 5% event rate for patients with risk factors only; 13% for patients with risk factors and one diseased vascular bed, 22% for patients with risk factors and two diseased vascular beds and 26% for patients with risk factors and three diseased vascular beds

- REACH demonstrates that up to 1.75 million CV events could be seen in those patients with multiple arterial disease in the US alone over the next 12 months(X)

For patients without a history of coronary,
'"/>

Page: 1 2 3 4
Related medicine technology :

1. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer

Post Your Comments:

( - The Reduction of Atherothrombosis fo...)REACH Registry Demonstrates That Multiple Arterial Disease,Locations Sharply Increase the Risk of Major CV Events in,Outpatients With Atherothrombosis,Health